Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists.

Muñoz-Moreno L, Carmena MJ, Schally AV, Prieto JC, Bajo AM.

Invest New Drugs. 2019 Jul 17. doi: 10.1007/s10637-019-00831-2. [Epub ahead of print]

PMID:
31312936
2.

Anticancer Activity of Dendriplexes against Advanced Prostate Cancer from Protumoral Peptides and Cationic Carbosilane Dendrimers.

Sánchez-Milla M, Muñoz-Moreno L, Sánchez-Nieves J, Malý M, Gómez R, Carmena MJ, de la Mata FJ.

Biomacromolecules. 2019 Mar 11;20(3):1224-1234. doi: 10.1021/acs.biomac.8b01632. Epub 2019 Feb 5.

PMID:
30669830
3.

Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.

Lee HS, Carmena M, Liskovykh M, Peat E, Kim JH, Oshimura M, Masumoto H, Teulade-Fichou MP, Pommier Y, Earnshaw WC, Larionov V, Kouprina N.

Cancer Res. 2018 Nov 1;78(21):6282-6296. doi: 10.1158/0008-5472.CAN-18-0894. Epub 2018 Aug 30.

4.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.

5.

Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.

Muñoz-Moreno L, Schally AV, Prieto JC, Carmena MJ, Bajo AM.

Prostate. 2018 Sep;78(12):915-926. doi: 10.1002/pros.23648. Epub 2018 May 10.

PMID:
29748961
6.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071.

7.

Editorial: Aurora Kinases: Classical Mitotic Roles, Non-Canonical Functions and Translational Views.

Pérez de Castro I, Carmena M, Prigent C, Glover DM.

Front Oncol. 2017 Mar 22;7:48. doi: 10.3389/fonc.2017.00048. eCollection 2017. No abstract available.

8.

Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.

Muñoz-Moreno L, Bajo AM, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2017 May 5;446:59-69. doi: 10.1016/j.mce.2017.02.011. Epub 2017 Feb 11.

PMID:
28193499
9.

PREditOR: a synthetic biology approach to removing heterochromatin from cells.

Molina O, Carmena M, Maudlin IE, Earnshaw WC.

Chromosome Res. 2016 Dec;24(4):495-509. Epub 2016 Dec 6.

10.

Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.

Vacas E, Muñoz-Moreno L, Valenzuela PL, Prieto JC, Schally AV, Carmena MJ, Bajo AM.

Peptides. 2016 Dec;86:153-161. doi: 10.1016/j.peptides.2016.11.004. Epub 2016 Nov 2.

PMID:
27816751
11.

Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.

Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.

Oncotarget. 2016 Aug 9;7(32):52195-52206. doi: 10.18632/oncotarget.10710.

12.

The Dawn of Aurora Kinase Research: From Fly Genetics to the Clinic.

Carmena M, Earnshaw WC, Glover DM.

Front Cell Dev Biol. 2015 Nov 17;3:73. doi: 10.3389/fcell.2015.00073. eCollection 2015. Review.

13.

VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells.

Fernández-Martínez AB, Carmena MJ, Bajo AM, Vacas E, Sánchez-Chapado M, Prieto JC.

Cell Signal. 2015 Feb;27(2):236-44. doi: 10.1016/j.cellsig.2014.11.005. Epub 2014 Nov 15.

PMID:
25446255
14.

Polo kinase regulates the localization and activity of the chromosomal passenger complex in meiosis and mitosis in Drosophila melanogaster.

Carmena M, Lombardia MO, Ogawa H, Earnshaw WC.

Open Biol. 2014 Nov;4(11):140162. doi: 10.1098/rsob.140162.

15.

Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models.

Muñoz-Moreno L, Arenas MI, Carmena MJ, Schally AV, Prieto JC, Bajo AM.

Invest New Drugs. 2014 Oct;32(5):871-82. doi: 10.1007/s10637-014-0131-4. Epub 2014 Jul 8.

PMID:
25000999
16.

Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression.

Vacas E, Muñoz-Moreno L, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Int J Biochem Cell Biol. 2014 Aug;53:295-301. doi: 10.1016/j.biocel.2014.05.036. Epub 2014 Jun 4.

PMID:
24905957
17.

Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice.

Vacas E, Arenas MI, Muñoz-Moreno L, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Cancer Lett. 2013 Aug 9;336(1):196-203. doi: 10.1016/j.canlet.2013.04.033. Epub 2013 May 7.

PMID:
23664888
18.

Flies stretch their cells to avoid a chromatin trap.

Carmena M.

J Cell Biol. 2012 Nov 26;199(5):719-21. doi: 10.1083/jcb.201210135.

19.

The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis.

Carmena M, Wheelock M, Funabiki H, Earnshaw WC.

Nat Rev Mol Cell Biol. 2012 Dec;13(12):789-803. doi: 10.1038/nrm3474. Review.

20.

Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma.

Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2013 Jan 30;365(2):212-22. doi: 10.1016/j.mce.2012.10.021. Epub 2012 Nov 1.

PMID:
23123564
21.

Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells.

Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Peptides. 2012 Dec;38(2):275-81. doi: 10.1016/j.peptides.2012.09.011. Epub 2012 Sep 19.

PMID:
23000305
22.

Abscission checkpoint control: stuck in the middle with Aurora B.

Carmena M.

Open Biol. 2012 Jul;2(7):120095. doi: 10.1098/rsob.120095.

23.

Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.

Muñoz-Moreno L, Arenas MI, Schally AV, Fernández-Martínez AB, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM.

Int J Cancer. 2013 Feb 15;132(4):755-65. doi: 10.1002/ijc.27716. Epub 2012 Jul 27.

24.

Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance.

Fernández-Martínez AB, Carmena MJ, Arenas MI, Bajo AM, Prieto JC, Sánchez-Chapado M.

Histol Histopathol. 2012 Aug;27(8):1093-101. doi: 10.14670/HH-27.1093.

PMID:
22763881
25.

Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.

Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ.

Biochim Biophys Acta. 2012 Oct;1823(10):1676-85. doi: 10.1016/j.bbamcr.2012.06.018. Epub 2012 Jun 21.

26.

Polo-like kinase-activating kinases: Aurora A, Aurora B and what else?

Archambault V, Carmena M.

Cell Cycle. 2012 Apr 15;11(8):1490-5. doi: 10.4161/cc.19724. Epub 2012 Apr 15.

27.

A mitosis-specific AMPK trimer?

Carmena M.

Cell Cycle. 2012 Apr 1;11(7):1269. doi: 10.4161/cc.19902. Epub 2012 Apr 1. No abstract available.

PMID:
22426423
28.

The chromosomal passenger complex activates Polo kinase at centromeres.

Carmena M, Pinson X, Platani M, Salloum Z, Xu Z, Clark A, Macisaac F, Ogawa H, Eggert U, Glover DM, Archambault V, Earnshaw WC.

PLoS Biol. 2012 Jan;10(1):e1001250. doi: 10.1371/journal.pbio.1001250. Epub 2012 Jan 24. Erratum in: PLoS Biol. 2012 Feb;10(2). doi:10.1371/annotation/7832f573-e0d9-465f-b5d4-0ac1014b6112.

29.

RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Bajo AM, Prieto JC.

Mol Cell Endocrinol. 2012 Jan 2;348(1):241-6. doi: 10.1016/j.mce.2011.08.031. Epub 2011 Aug 27.

PMID:
21896307
30.

Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.

Fernández-Martínez AB, Bajo AM, Isabel Arenas M, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Cancer Lett. 2010 Dec 18;299(1):11-21. doi: 10.1016/j.canlet.2010.07.019. Epub 2010 Aug 14.

PMID:
20709445
31.

Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.

Valdehita A, Bajo AM, Fernández-Martínez AB, Arenas MI, Vacas E, Valenzuela P, Ruíz-Villaespesa A, Prieto JC, Carmena MJ.

Peptides. 2010 Nov;31(11):2035-45. doi: 10.1016/j.peptides.2010.07.024. Epub 2010 Aug 5.

PMID:
20691743
32.

SUMOylation modulates the function of Aurora-B kinase.

Fernández-Miranda G, Pérez de Castro I, Carmena M, Aguirre-Portolés C, Ruchaud S, Fant X, Montoya G, Earnshaw WC, Malumbres M.

J Cell Sci. 2010 Aug 15;123(Pt 16):2823-33. doi: 10.1242/jcs.065565. Epub 2010 Jul 27.

33.

Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).

Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM.

Int J Cancer. 2010 Oct 15;127(8):1813-22. doi: 10.1002/ijc.25192.

34.

Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins.

Carmena M, Ruchaud S, Earnshaw WC.

Curr Opin Cell Biol. 2009 Dec;21(6):796-805. doi: 10.1016/j.ceb.2009.09.008. Review.

35.

Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.

Fernández-Martínez AB, Bajo AM, Valdehita A, Isabel Arenas M, Sánchez-Chapado M, Carmena MJ, Prieto JC.

Peptides. 2009 Dec;30(12):2357-64. doi: 10.1016/j.peptides.2009.09.018. Epub 2009 Sep 20.

PMID:
19772879
36.

AMPK: Sensing energy to travel in mitosis.

Carmena M.

Cell Cycle. 2009 Sep 1;8(17):2682-3. Epub 2009 Sep 1. No abstract available.

PMID:
19717974
37.

Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.

Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Prostate. 2009 May 15;69(7):774-86. doi: 10.1002/pros.20930.

PMID:
19189304
38.

Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.

Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC.

Mol Cell Endocrinol. 2009 Apr 10;302(1):41-8. doi: 10.1016/j.mce.2008.11.024. Epub 2008 Dec 3.

PMID:
19101605
39.

Dual roles of Incenp crucial to the assembly of the acentrosomal metaphase spindle in female meiosis.

Colombié N, Cullen CF, Brittle AL, Jang JK, Earnshaw WC, Carmena M, McKim K, Ohkura H.

Development. 2008 Oct;135(19):3239-46. doi: 10.1242/dev.022624. Epub 2008 Aug 28.

40.

Cytokinesis: the final stop for the chromosomal passengers.

Carmena M.

Biochem Soc Trans. 2008 Jun;36(Pt 3):367-70. doi: 10.1042/BST0360367. Review.

PMID:
18481960
41.

The chromosomal passenger complex: one for all and all for one.

Ruchaud S, Carmena M, Earnshaw WC.

Cell. 2007 Oct 19;131(2):230-1.

42.

Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.

Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.

Int J Oncol. 2007 Nov;31(5):1223-30.

PMID:
17912451
43.

Chromosomal passengers: conducting cell division.

Ruchaud S, Carmena M, Earnshaw WC.

Nat Rev Mol Cell Biol. 2007 Oct;8(10):798-812. Review.

PMID:
17848966
44.

Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM.

Regul Pept. 2007 Dec 4;144(1-3):101-8. Epub 2007 Jun 28.

PMID:
17683807
45.

Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model.

Collado B, Carmena MJ, Clemente C, Prieto JC, Bajo AM.

Peptides. 2007 Sep;28(9):1896-901. Epub 2007 May 3.

PMID:
17544169
46.

Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.

Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2007 May 30;270(1-2):8-16. Epub 2007 Jan 21.

PMID:
17434257
47.

INCENP and Aurora B promote meiotic sister chromatid cohesion through localization of the Shugoshin MEI-S332 in Drosophila.

Resnick TD, Satinover DL, MacIsaac F, Stukenberg PT, Earnshaw WC, Orr-Weaver TL, Carmena M.

Dev Cell. 2006 Jul;11(1):57-68.

48.

Hypoxia regulation of expression and angiogenic effects of vasoactive intestinal peptide (VIP) and VIP receptors in LNCaP prostate cancer cells.

Collado B, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2006 Apr 25;249(1-2):116-22. Epub 2006 Mar 23.

PMID:
16563610
49.

Drosophila Incenp is required for cytokinesis and asymmetric cell division during development of the nervous system.

Chang CJ, Goulding S, Adams RR, Earnshaw WC, Carmena M.

J Cell Sci. 2006 Mar 15;119(Pt 6):1144-53. Epub 2006 Feb 28.

50.

INCENP at the kinase crossroads.

Carmena M, Earnshaw WC.

Nat Cell Biol. 2006 Feb;8(2):110-1. No abstract available.

PMID:
16450006

Supplemental Content

Loading ...
Support Center